-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Click on the picture to register now June 11, 2021/DrugFunds News/--On June 9, 2021, a clinical-stage regenerative medicine company ViaCyte announced the completion of a US$45 million financing
.
The proceeds from the financing will be used to fund the most advanced combination of stem cell-derived therapies aimed at providing a functional cure for patients with type 1 diabetes
.
With this financing, the company's D round of financing totaled more than 115 million US dollars
.
The financing includes the long-term participation of existing investors Bain Capital Life Sciences, TPG Capital, RA Capital Management, Sanderling Ventures and insiders
.
New investors in this round include Adage Capital Partners, Invus Group, Asymmetry Ventures and Artis Ventures
.
Brittany Bradrick, Chief Financial Officer and Chief Operating Officer of ViaCyte, said: "We are very pleased to receive the support of our outstanding existing investors and new investors in this financing
.
When our product candidates advance to the clinical stage, we are The mission of developing functional treatments for patients with type 1 diabetes and creating value for our shareholders has become clearer, leading to an optimization of the balance sheet and further development of ViaCyte
.
"ViaCyte President and CEO Michael Yang commented: "In the 100 years since the discovery of insulin, there have been few paradigm shift innovations
.
ViaCyte's stem cell-derived therapy product portfolio is the world's leading international original (first-in-category, first-in-class) product, which represents a major progress in the search for functional treatments for type 1 diabetes and other chronic diseases in the future
.
This financing will allow us to accelerate the development of three new therapies in the pipeline to reduce the burden faced by patients with type 1 diabetes
.
Some of our therapies have entered the clinical stage, and we look forward to exciting progress in our clinical trials next year
.
"Recommended reading: CRISPR Therapeutics and ViaCyte are partnering with ViaCyte to create "off-the-shelf" stem cell therapy for type 1 diabetes, which is expected to overcome the problem of immune rejection.
.
Cell replacement therapy derived from pluripotent stem cells: ViaCyte's pluripotent stem cell-based technology aims to solve the limitations of donor pancreatic islet transplantation, and represents a major advancement in the functional treatment of type 1 diabetes
.
2.
Medical device system for cell encapsulation and implantation: ViaCyte's implantable medical device is designed to carry the company's cell replacement therapy, so that cells can survive and function
.
Through these technologies, ViaCyte uses off-the-shelf, CRISPR-Cas9-edited stem cell-derived pancreatic cell replacement therapy to treat type 1 diabetes
.
The company's current R&D pipeline includes three types of products: PEC-Direct, PEC-Encap and PEC-QT
.
PEC-01 cell is the active drug substance shared by these three projects
.
▲ ViaCyte R&D pipeline (Source: official website) Currently, diabetes is a global health problem and one of the most important causes of death, affecting more than 400 million people worldwide, and the prevalence is increasing year by year
.
In 2019, the Global Diabetes Map (9th edition) released by the International Diabetes Federation (IDF) shows that the number of diabetes patients worldwide is increasing, with an average global growth rate of 51%.
There are currently 463 million diabetic patients, according to the growth trend until 2045 There will be 700 million diabetic patients worldwide
.
The number of people suffering from diabetes in China ranks first in the world, with approximately 116.
4 million people
.
T1D accounts for about 5% to 10% of the total number of diabetic patients.
It is obviously characterized by early onset, which usually has onset in childhood or adolescence
.
At present, the main method of diabetes treatment is insulin injection and blood glucose monitoring
.
However, traditional insulin supplementation cannot achieve fundamental treatment, and the control of diabetic complications is also insufficient
.
There are highly unmet medical needs
.
In 2019, the US "Time" magazine included stem cell treatment of diabetes in the list of 12 innovative inventions that will change medical care in the next decade
.
Therefore, more and more companies/institutions are developing stem cell treatment projects for T1D
.
For more details, click on the QR code to read the reference materials in full: 1.
https:// -portfolio-of-stem-cell-derived-therapies-for-type-1-diabetes-301308714.
html affirms: The copyright of the content published in the medicine financing belongs to the original author and the right holder
.
Any opinions and information appearing in the article are for reference only and not as investment decisions
.
If you are interested in the above-mentioned projects or have investment and financing news to disclose, or seek interview reports, you can contact the staff: 13621634647 (same number on WeChat)
.
The proceeds from the financing will be used to fund the most advanced combination of stem cell-derived therapies aimed at providing a functional cure for patients with type 1 diabetes
.
With this financing, the company's D round of financing totaled more than 115 million US dollars
.
The financing includes the long-term participation of existing investors Bain Capital Life Sciences, TPG Capital, RA Capital Management, Sanderling Ventures and insiders
.
New investors in this round include Adage Capital Partners, Invus Group, Asymmetry Ventures and Artis Ventures
.
Brittany Bradrick, Chief Financial Officer and Chief Operating Officer of ViaCyte, said: "We are very pleased to receive the support of our outstanding existing investors and new investors in this financing
.
When our product candidates advance to the clinical stage, we are The mission of developing functional treatments for patients with type 1 diabetes and creating value for our shareholders has become clearer, leading to an optimization of the balance sheet and further development of ViaCyte
.
"ViaCyte President and CEO Michael Yang commented: "In the 100 years since the discovery of insulin, there have been few paradigm shift innovations
.
ViaCyte's stem cell-derived therapy product portfolio is the world's leading international original (first-in-category, first-in-class) product, which represents a major progress in the search for functional treatments for type 1 diabetes and other chronic diseases in the future
.
This financing will allow us to accelerate the development of three new therapies in the pipeline to reduce the burden faced by patients with type 1 diabetes
.
Some of our therapies have entered the clinical stage, and we look forward to exciting progress in our clinical trials next year
.
"Recommended reading: CRISPR Therapeutics and ViaCyte are partnering with ViaCyte to create "off-the-shelf" stem cell therapy for type 1 diabetes, which is expected to overcome the problem of immune rejection.
.
Cell replacement therapy derived from pluripotent stem cells: ViaCyte's pluripotent stem cell-based technology aims to solve the limitations of donor pancreatic islet transplantation, and represents a major advancement in the functional treatment of type 1 diabetes
.
2.
Medical device system for cell encapsulation and implantation: ViaCyte's implantable medical device is designed to carry the company's cell replacement therapy, so that cells can survive and function
.
Through these technologies, ViaCyte uses off-the-shelf, CRISPR-Cas9-edited stem cell-derived pancreatic cell replacement therapy to treat type 1 diabetes
.
The company's current R&D pipeline includes three types of products: PEC-Direct, PEC-Encap and PEC-QT
.
PEC-01 cell is the active drug substance shared by these three projects
.
▲ ViaCyte R&D pipeline (Source: official website) Currently, diabetes is a global health problem and one of the most important causes of death, affecting more than 400 million people worldwide, and the prevalence is increasing year by year
.
In 2019, the Global Diabetes Map (9th edition) released by the International Diabetes Federation (IDF) shows that the number of diabetes patients worldwide is increasing, with an average global growth rate of 51%.
There are currently 463 million diabetic patients, according to the growth trend until 2045 There will be 700 million diabetic patients worldwide
.
The number of people suffering from diabetes in China ranks first in the world, with approximately 116.
4 million people
.
T1D accounts for about 5% to 10% of the total number of diabetic patients.
It is obviously characterized by early onset, which usually has onset in childhood or adolescence
.
At present, the main method of diabetes treatment is insulin injection and blood glucose monitoring
.
However, traditional insulin supplementation cannot achieve fundamental treatment, and the control of diabetic complications is also insufficient
.
There are highly unmet medical needs
.
In 2019, the US "Time" magazine included stem cell treatment of diabetes in the list of 12 innovative inventions that will change medical care in the next decade
.
Therefore, more and more companies/institutions are developing stem cell treatment projects for T1D
.
For more details, click on the QR code to read the reference materials in full: 1.
https:// -portfolio-of-stem-cell-derived-therapies-for-type-1-diabetes-301308714.
html affirms: The copyright of the content published in the medicine financing belongs to the original author and the right holder
.
Any opinions and information appearing in the article are for reference only and not as investment decisions
.
If you are interested in the above-mentioned projects or have investment and financing news to disclose, or seek interview reports, you can contact the staff: 13621634647 (same number on WeChat)
